Xenetic Biosciences (NASDAQ:XBIO) Stock Price Passes Above Fifty Day Moving Average – What’s Next?

Xenetic Biosciences, Inc. (NASDAQ:XBIO) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.89 and traded as high as $2.96. Xenetic Biosciences shares last traded at $2.85, with a volume of 18,955 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Xenetic Biosciences Stock Down 3.7%

The firm has a 50 day moving average price of $2.89 and a 200 day moving average price of $2.81. The stock has a market capitalization of $6.53 million, a PE ratio of -2.37 and a beta of 2.10.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) EPS for the quarter. The firm had revenue of $0.66 million during the quarter. Xenetic Biosciences had a negative net margin of 70.03% and a negative return on equity of 39.28%.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC raised its holdings in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 178,509 shares of the company’s stock after purchasing an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned approximately 7.80% of Xenetic Biosciences worth $387,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.